Latebreakers: Warnings added for Exjade

Article

Changes have been made to the prescribing information for deferasirox (Exjade, Novartis) following postmarketing reports of acute renal failure and cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia.

Changes have been made to the prescribing information for deferasirox (Exjade, Novartis) following postmarketing reports of acute renal failure and cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia. Fatalities were reported in both groups; however, most occurred in patients with comorbidities and preexisting disorders. According to Novartis, the relationship of these adverse reactions and deaths to deferasirox therapy is uncertain. Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients two years of age and older.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.